Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2005 2
2006 1
2007 1
2008 2
2009 2
2010 4
2011 1
2012 1
2014 1
2015 2
2017 2
2019 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Sanz MA, et al. Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Blood. 2019. PMID: 30803991 Free PMC article. Review.
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder …
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review c …
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. Sanz MA, et al. Blood. 2009 Feb 26;113(9):1875-91. doi: 10.1182/blood-2008-04-150250. Epub 2008 Sep 23. Blood. 2009. PMID: 18812465 Free article. Review.
Together with providing current indications on genetic diagnosis, modern risk-adapted front-line therapy and salvage treatment, the review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL …
Together with providing current indications on genetic diagnosis, modern risk-adapted front-line therapy and salvage treatment, the review c …
Arsenic trioxide - An old drug rediscovered.
Emadi A, Gore SD. Emadi A, et al. Blood Rev. 2010 Jul-Sep;24(4-5):191-9. doi: 10.1016/j.blre.2010.04.001. Epub 2010 May 15. Blood Rev. 2010. PMID: 20471733 Free PMC article. Review.
Over the last 17 years, clinical trials conducted worldwide have demonstrated the efficacy of arsenic trioxide (As(2)O(3)) in the treatment of relapsed acute promyelocytic leukemia (APL). ...Therapeutic doses of As(2)O(3) are well tolerated, with no evidence of long-term t …
Over the last 17 years, clinical trials conducted worldwide have demonstrated the efficacy of arsenic trioxide (As(2)O(3)) in the tre …
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D, Tallman MS. Douer D, et al. J Clin Oncol. 2005 Apr 1;23(10):2396-410. doi: 10.1200/JCO.2005.10.217. J Clin Oncol. 2005. PMID: 15800332 Review.
Arsenic trioxide has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces complete remission in 87% of patients and molecular remission in 83% of patients. Two-year ove …
Arsenic trioxide has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). In …
The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia.
Mohammadzadeh Z, Omidkhoda A, Chahardouli B, Hoseinzadeh G, Moghaddam KA, Mousavi SA, Rostami S. Mohammadzadeh Z, et al. BMC Cancer. 2021 Jan 9;21(1):46. doi: 10.1186/s12885-021-07783-y. BMC Cancer. 2021. PMID: 33422029 Free PMC article.
BACKGROUND: Although arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are well-tolerated and effective treatments for Acute Promyelocytic Leukemia (APL), Differentiation Syndrome (DS) is a lethal side effect in some patients. ...
BACKGROUND: Although arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are well-tolerated and effective treatments for Acute Promyel …
Arsenic trioxide: safety issues and their management.
Au WY, Kwong YL. Au WY, et al. Acta Pharmacol Sin. 2008 Mar;29(3):296-304. doi: 10.1111/j.1745-7254.2008.00771.x. Acta Pharmacol Sin. 2008. PMID: 18298894 Review.
During induction therapy in APL, a leucocytosis may occasionally occur, which can be associated with fluid accumulation and pulmonary infiltration. The condition is similar to the APL differentiation syndrome during treatment with all-trans retinoic acid, and …
During induction therapy in APL, a leucocytosis may occasionally occur, which can be associated with fluid accumulation and pulmonary infilt …
Treatment of acute promyelocytic leukemia by retinoids.
Fenaux P, Wang ZZ, Degos L. Fenaux P, et al. Curr Top Microbiol Immunol. 2007;313:101-28. doi: 10.1007/978-3-540-34594-7_7. Curr Top Microbiol Immunol. 2007. PMID: 17217041 Review.
Combination treatment probably also reduces the incidence of initial failures, and complete remission (CR) rates greater than 90% are now regularly reported in large multicenter trials. Some randomized studies strongly suggest that prolonged maintenance treatment (for 1 or …
Combination treatment probably also reduces the incidence of initial failures, and complete remission (CR) rates greater than 90% are now re …
Risk/benefit profile of arsenic trioxide.
Rust DM, Soignet SL. Rust DM, et al. Oncologist. 2001;6 Suppl 2:29-32. doi: 10.1634/theoncologist.6-suppl_2-29. Oncologist. 2001. PMID: 11331438 Free article. Review.
In the mid-1990s, studies from China reported the effective use of arsenic trioxide in achieving complete remission in patients with APL. In the United States, a multicenter trial of this agent in 40 patients with relapsed APL following conventional therapy confirmed the p …
In the mid-1990s, studies from China reported the effective use of arsenic trioxide in achieving complete remission in patients with APL. In …
ATRA treatment slowed P-selectin-mediated rolling of flowing HL60 cells in a mechano-chemical-dependent manner.
Dong X, Peng S, Ling Y, Huang B, Tu W, Sun X, Li Q, Fang Y, Wu J. Dong X, et al. Front Immunol. 2023 Apr 24;14:1148543. doi: 10.3389/fimmu.2023.1148543. eCollection 2023. Front Immunol. 2023. PMID: 37168856 Free PMC article.
All-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL) toward granulocytes may trigger APL differentiation syndrome (DS), but there is less knowledge about the mechano-chemical regulation mechanism of APL DS under the mec …
All-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL) toward granulocytes may trigger APL d …
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Tallman M, Douer D, Gore S, Powell BL, Ravandi F, Rowe J, Ranganathan A, Sanz MA. Tallman M, et al. Clin Lymphoma Myeloma Leuk. 2010 Oct;10 Suppl 3:S122-6. doi: 10.3816/CLML.2010.s.023. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21115429
The integration of all-trans-retinoic acid (ATRA) with anthracycline chemotherapy into up-front regimens for acute promyelocytic leukemia (APL) has produced striking improvements in clinical outcomes, making APL one of the most curable forms of hematologic malignancies in …
The integration of all-trans-retinoic acid (ATRA) with anthracycline chemotherapy into up-front regimens for acute promyelocytic leukemia (A …
22 results